AlphAIAlphAI — Financial news for AI agents
SEC EDGAROCT 301 min read$SNDX

Podlesak Dennis sold $114K of SNDX

Podlesak Dennis sold 8,000 shares of Syndax Pharmaceuticals Inc (SNDX) at $14.21 ($0.11M total) on 2026-10-29 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Podlesak Dennis
Published Oct 30, 2026, 11:09 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 30, 2026, 11:13 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$SNDX
Neutral
medium confidence
Mentioned
$SNDX
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SNDXNeutralLow
01

Why it matters

The transaction is a primary disclosure but modest in size, offering limited trading insight.

02

Market read

Small insider sale with limited price impact; useful for compliance monitoring rather than immediate trade decisions.

03

What to watch

Potential upcoming clinical data releases that may offset any negative sentiment from the sale.

Relevance 3/10Novelty 3/10Timing: after-hours filing

Background

Form 4 filings disclose insider transactions; a director's sale via a pre-arranged plan is a standard disclosure.

Company-level read

Ticker impact

$SNDXNeutralMedium confidence
Context

Director Dennis Podlesak sold 8,000 shares for $113,716 via a 10b5-1 plan, reducing his stake to 239,763 shares.

Expected impact

likely slight pressure as the market prices in the insider sell

Evidence & confidence

A $113k sale by a director is material enough to be noted but unlikely to move the stock significantly.

Market effects

Sector

Minimal impact on the biotech sector; insider sales are routine.

Regional

No regional effect.

Global

Limited to investors tracking SNDX.

Counterpoint

What could challenge this read

The sale could be unrelated to company fundamentals and merely portfolio rebalancing.

Key entities

  • company
    Syndax Pharmaceuticals Inc

    Biotech firm listed on NASDAQ under ticker SNDX.

  • person
    Dennis Podlesak

    Director of Syndax who executed the sale.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

SNDX insider trading history →

Related articles

NOV 2
$SNDXHighAI 8/10

Syndax Reports Third Quarter 2026 Financial Results and Provides Business Update

Syndax Pharmaceuticals Inc (SNDX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Syndax Reports Third Quarter 2026 Financial Results and Provides Business Update • Total revenue of $83.3 million in 3Q26, an 82% year-over-year increase – Revuforj ® (revumenib) net revenue of $60.7 million in 3Q26, a 90% y/y increase, underscores leadership in R/R

SEC EDGAR 8-K2 min
NOV 2
$SNDXLow

Syndax's new finance chief starts Nov. 9; his predecessor stays through year-end

Syndax Pharmaceuticals (SNDX) appointed Aaron A. Ondrey as CFO, effective Nov. 9, 2026. Keith A. Goldan, the outgoing CFO, will stay until year-end to support the transition. Ondrey has 25 years of biotech finance experience, previously serving as CFO at Beren Therapeutics and Rocket Pharmaceuticals. Goldan led Syndax's financial strategy during key growth periods, including FDA approvals for Revuforj and Niktimvo.

stocktitan.net1 min
NOV 2
$SNDXMed

About 20% more patients started Syndax's leukemia drug in Q3 than Q2; new data are expected in Q4.

Syndax Pharmaceuticals reported Q3 2026 revenue of $60.7M for Revuforj and $67.4M for Niktimvo, with Revuforj showing 90% YoY growth. The company expects new data on Revuforj in Q4 2026 from multiple clinical trials and real-world studies. Syndax plans to initiate the RAVEN trial in Q4 2026 and the MenTain trial in Q1 2027. The company will host a conference call today at 4:30 p.m. ET.

stocktitan.net2 min
OCT 14
$SNDXMedAI 8/10

Syndax Stock Falls 16% as Phase II Fibrosis Study Misses Primary Goal

Syndax Pharmaceuticals' stock fell 15.7% after its Phase II study of axatilimab in idiopathic pulmonary fibrosis (IPF) failed to meet the primary endpoint. The company will discontinue IPF development, but continues cGVHD programs. Axatilimab is already FDA-approved for cGVHD. Year-to-date, SNDX shares have dropped 33.6%.

zacks.com2 min
OCT 13
$CMed

Crude Oil Edges Higher; Citigroup Earnings Top Views

Citigroup (NYSE:C) reported Q3 earnings of $2.85 per share, beating estimates. Bumble (NASDAQ:BMBL) surged 56% after a buyout deal. BIO-Key (NASDAQ:BKYI) rose 139% on a government security contract. Fermi (NASDAQ:FRMI) gained 21% on a credit agreement. Pershing Square (NYSE:PS) fell 11% after a downgrade. Cipher Digital (NASDAQ:CIFR) dropped 14% on a convertible notes offering. Syndax (NASDAQ:SNDX) declined 17% after a trial failure. Oil rose 0.4% to $94.13, while gold and silver fell.

benzinga.com7 min
OCT 13
$SNDXMedAI 8/10

Stifel maintains Syndax stock rating after trial failure

Stifel maintained its Buy rating and $40 price target on Syndax Pharmaceuticals (SNDX) after the company's Phase 2 trial for axatilimab in idiopathic pulmonary fibrosis failed. Syndax will halt further development of the drug for this indication. Stifel noted the setback but kept its positive outlook on Revuforj revenue growth and Niktimvo's potential. SNDX shares fell about 15% post-announcement, trading near their 52-week low.

investing.com2 min